相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study
Yusuf Yazici et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?
Anne M. Kerola et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate
P. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Tocilizumab - A novel therapy for non-organ-specific autoimmune diseases
Lisa Kaly et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2012)
Tocilizumab treatment for neuro-Behcet's disease, the first report
Lee S. Shapiro et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2012)
The role of tocilizumab in the management of rheumatoid arthritis
Zoe Ash et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Evaluating disease activity in rheumatoid arthritis: Which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI
Cecile Gaujoux-Viala et al.
JOINT BONE SPINE (2012)
A case of Beh‡et's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab
Toru Hirano et al.
MODERN RHEUMATOLOGY (2012)
Assessing the safety of biologic agents in patients with rheumatoid arthritis
Andrea Rubbert-Roth
RHEUMATOLOGY (2012)
Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI
Atsushi Kaneko et al.
RHEUMATOLOGY INTERNATIONAL (2012)
Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica
S. Unizony et al.
ARTHRITIS CARE & RESEARCH (2012)
Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
Sergei I. Grivennikov et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
Moetaza M. Soliman et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Interleukin-6 Receptor Inhibition With Tocilizumab and Attainment of Disease Remission in Rheumatoid Arthritis The Role of Acute-Phase Reactants
Josef S. Smolen et al.
ARTHRITIS AND RHEUMATISM (2011)
2011 ACR/ARHP Annual Scientific Meeting Late-Breaking Abstracts
ARTHRITIS AND RHEUMATISM (2011)
Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients With Inadequate Responses to Methotrexate Results From the Double-Blind Treatment Phase of a Randomized Placebo-Controlled Trial of Tocilizumab Safety and Prevention of Structural Joint Damage at One Year
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2011)
The Unholy Trinity: Inflammation, Cytokines, and STAT3 Shape The Cancer Microenvironment
Ning Li et al.
CANCER CELL (2011)
Comparison of composite disease activity indices for rheumatoid arthritis
Toshihiro Matsui et al.
MODERN RHEUMATOLOGY (2011)
Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials
Laura Campbell et al.
RHEUMATOLOGY (2011)
Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody
Keiichi Sumida et al.
RHEUMATOLOGY (2011)
Therapeutic effect of tocilizumab on two patients with polymyositis
Masashi Narazaki et al.
RHEUMATOLOGY (2011)
Tocilizumab in Refractory Adult Still's Disease
Xavier Puechal et al.
ARTHRITIS CARE & RESEARCH (2011)
Integrated safety in tocilizumab clinical trials
Michael H. Schiff et al.
ARTHRITIS RESEARCH & THERAPY (2011)
The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis
Misato Hashizume et al.
ARTHRITIS (2011)
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
G. Jones et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Demyelinating events in rheumatoid arthritis after drug exposures
Sasha Bernatsky et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Total cholesterol and LDL levels decrease before rheumatoid arthritis
Elena Myasoedova et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Tocilizumab in Systemic Lupus Erythematosus Data on Safety, Preliminary Efficacy, and Impact on Circulating Plasma Cells From an Open-Label Phase I Dosage-Escalation Study
Gabor G. Illei et al.
ARTHRITIS AND RHEUMATISM (2010)
The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab
Yoshihito Shima et al.
RHEUMATOLOGY (2010)
The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis
Srinivasan Srirangan et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2010)
Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
N. Nishimoto et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Leukoencephalopathy with Cognitive Impairment following Tocilizumab for the Treatment of Rheumatoid Arthritis (RA)
Katsuya Kobayashi et al.
INTERNAL MEDICINE (2009)
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
Norihiro Nishimoto et al.
MODERN RHEUMATOLOGY (2009)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2008)
Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus
Sahena Haque et al.
CURRENT OPINION IN LIPIDOLOGY (2008)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S. Smolen et al.
LANCET (2008)
Biologic treatment of rheumatoid arthritis and the risk of malignancy - Analyses from a large US observational study
Frederick Wolfe et al.
ARTHRITIS AND RHEUMATISM (2007)
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
Norihiro Nishimoto et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways
Liang Zhou et al.
NATURE IMMUNOLOGY (2007)
Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor
Naoko Yoshio-Hoshino et al.
CANCER RESEARCH (2007)
Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease
Masashi Matsuyama et al.
INTERNAL MEDICINE (2007)
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
R. N. Maini et al.
ARTHRITIS AND RHEUMATISM (2006)
Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer
Stefan Rose-John et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2006)
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
T Bongartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low - results from RABBIT, the German biologics register
Joachim Listing et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family
M Mihara et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2005)
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
D Aletaha et al.
ARTHRITIS RESEARCH & THERAPY (2005)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
L Klareskog et al.
LANCET (2004)
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody - A multicenter, double-blind, placebo-controlled trial
N Nishimoto et al.
ARTHRITIS AND RHEUMATISM (2004)
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation
T Ganz
BLOOD (2003)
Interleukin-6 stimulates lipolysis and fat oxidation in humans
G van Hall et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-κB ligand, osteoprotegerin, and receptor activator of NF-κB in mouse calvariae
P Palmqvist et al.
JOURNAL OF IMMUNOLOGY (2002)
The epidemiology of rheumatoid arthritis
SE Gabriel
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2001)
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
JM Bathon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
